ATAI Aug 2023 5.000 call
| Previous Close | 0.0500 |
| Open | 0.0600 |
| Bid | 0.0000 |
| Ask | 0.1500 |
| Strike | 5.00 |
| Expire Date | 2023-08-18 |
| Day's Range | 0.0500 - 0.0600 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 891 |
- GlobeNewswire
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophreniaGRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical developmentCOMP360: Recently announced acceleration of the Pivotal Trial 1 (COMP 005) part of the phase 3 program, with top line data now expected in the summer of 2024Corporate: As a result of our recent restructuring and pipeline updates, the company has extended its cash r
- GlobeNewswire
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference. Details of the company’s panel participation are as follows: Cowen 43rd Annual Health Care Conference Format: Neuropsych Corporate Panel Date and Time: Monday, March 6th, 12:50 p.m. – 1:20 p.m. ET Location: Boston, MA A live webc
- News Direct
Trippy Trading: Top Psychedelic Stocks For 2023
When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scie...
